Novo Nordisk reported 10% sales growth in 2025, driven by strong obesity care expansion and the FDA approval of the first oral Wegovy pill, supporting its long-term GLP-1 growth strategy.
Written By: Sana Khan BPharm
Reviewed By: Pharmacally Editorial Team
Novo Nordisk has reported steady performance in 2025, delivering 10% sales growth at constant exchange rates, supported mainly by strong demand for its obesity medicines. The company said the approval and early uptake of the first oral Wegovy pill represents an important step in expanding obesity treatment access and driving future growth.
Obesity Care Remains the Main Growth Engine
Novo Nordisk’s obesity and diabetes care business continued to grow through 2025, with obesity therapies standing out as the biggest contributor.
- Obesity care sales rose 26% in Danish kroner
- GLP-1 diabetes sales grew more modestly during the year
This reflects Novo Nordisk’s increasing focus on obesity as a long-term driver of expansion.
Wegovy Pill Approval Marks a Major Turning Point
A major highlight came on 22 December 2025, when the US FDA approved the first oral GLP-1 treatment for obesity, once-daily oral semaglutide 25 mg, branded as the Wegovy pill.
The product launched in early January 2026, and Novo Nordisk reported encouraging early prescription uptake. The company views the oral Wegovy pill as a key innovation that could help reach more patients, particularly those seeking an alternative to injectable therapies.
Operating Profit Impacted by Transformation Costs
Novo Nordisk reported that operating profit was slightly lower in Danish kroner, mainly due to costs linked to a company-wide transformation effort. Excluding these costs, underlying profitability showed stronger growth.
Despite these expenses, the company maintained solid momentum heading into 2026.
Pipeline Progress Supports Next-Generation Growth
Novo Nordisk also highlighted important R&D developments, including:
- Phase 2 results for zenagamtide, showing meaningful weight loss and improved blood sugar control in type 2 diabetes
- Successful completion of the phase 3 REIMAGINE 2 trials for CagriSema in diabetes
- Regulatory submissions in the US for higher-dose semaglutide and CagriSema in obesity
These next-generation therapies are expected to strengthen Novo Nordisk’s leadership in the expanding GLP-1 market.
2026 Outlook: Challenges but Strong Confidence in Volume Growth
Novo Nordisk acknowledged that 2026 may bring pricing pressure and greater competition. However, the company remains confident that new launches, including Wegovy pill, will support continued growth through broader patient access and higher treatment volumes.
CEO Mike Doustdar said Novo Nordisk reached nearly 46 million people with its treatments in 2025 and is encouraged by the strong early demand for Wegovy pill.
Shareholder Returns
The company plans to propose a final dividend for 2025 at its Annual General Meeting in March 2026, alongside a new share repurchase programme.
Earnings Call
Novo Nordisk will hold its earnings call on 4 February 2026, with a webcast available through the Investors section of the company’s website.
Reference
Novo Nordisk’s sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025, 03 February 2026, News Details